IPVM Scientific Study Published by Journal of Biomedical Optics Shows Systematic Temperature Screening Manipulation
In a new peer-reviewed study published in the Journal of Biomedical Optics, IPVM researchers found that devices from 7 different manufacturers systematically manipulate temperature readings regularly reporting fever-level temperatures as normal. Watch the video to learn more:
The title of the study is "Globally deployed COVID-19 fever screening devices using infrared thermographs consistently normalize high readings to afebrile range":
Moreover, the Washington Post published a story on this: Those fever scanners that everyone is using to fight covid can be wildly inaccurate, researchers find.
*** *****, ********* ** ****’* *********, PA ********, ** *** ***** **************-********* proof ** ********** *********** ************. ***** 7 ******* ********* ****** **** (****** or **********) *********** ********* ** * market **** *** ******** **** ***, unapproved ******* ******-***** ********* ***** *** COVID-19 ******** *****.
*** ***** ***** ***** *** * control (*** *******) ******* ***** *** then *** * ****** *******:
***** ***** ****** ******* ** ****** temperature ** ****** ************ ***** ***** findings *** * **** ** ****** health ***** **** ******** ****** ****** as ******, ** *** ***** *****:
***** **** ***** ******* *** ******** for ******** ********* ** ******** ********** disease ************, *** *** *** ******** employed, *** ************ *** ******* ********* of ********* *** * ********** ***** sense ** ********.
*** *********** ************* *** *** ********* by *************, **** ** ********** ** clinical *****, *** ******** **** *** expectations ** ********* ******. *********, *** study ****** ******* ********* **** *** legitimacy ** *********** ********* ***** ****** the ********.
Study ***** ************ *********
** *** * *******, ***** **** consistent (*********) *********** ******* ****** ******** and *** *******’* ***********. *** *********** increased ******** ** ***** ************, *** decreased ******** ** ****** ************. ** contrast, *** ******* ******* ****** ** such ***********; **** **** ******** *** consistent ****** *** ****** ** *******.
*** ***** ***** ************ *** ************ pattern ***** ****** ****** *******:
***** ** * *********** ******** ** these ***********, *** ***** ********* **** they ****** **** * ********-***** ************ algorithm. *** ********* ******* ************ ******* the ***** ****, ******* *** ****** (or *****) *** ***********, *** ****** the **********. ** ****** ** *** study:
***** ********, ***** ******** ******* * human-target ******** ********* **** ******* *** recorded *********** ** *** ***** ****, with *** ********* *********** ******* ** the **** ******* ********.Thus, * ***** ******* ******* ***** ****** ** ******** ** ****. [emphasis added]
FDA **********
** *** **, *** *** ********* human *********** ********* ******** ** ******* devices. **********, *** ****** ******** **** all *** ******* *** ****** *** safety *** *************; **** ** ***** as * *** (*) *********. ***** ***** ****, *** *** ************* **** "*** *** ****** ** object" ** *** ***** ** ********* products ** ***** *** ** "***** risk".
********* *** ***’* ************, * ***** of ******** *********** ********* **** ******** to ******. ** ****’* **** ****** count, ***** ****** **** **** *** *******. ****** *** ******* *** *********** screening ****** ****** *** ********.
FDA ********
***** ********** **** *********, *** *** *** ***** *** first ******:
** ******** *****, ******* ***** *** Washington **** ********* *** ******** ******** with *** **** *** **** **************, the ****** ****** ******* ************ **** ******** *** ** *** devices ***** **** ** ********** ************ and “******* *********** ******* ****** ****** risks.”
*** ******** *** ******* **** ***** action **** *** *** *** ***** regulatory ******** ****** *** ***** **** as *** ****** **** ***** ******* become ****** **********.
Update (**/**/**): ********* ********
********* *** ********* ** *** *****, saying:
** ***** **** ** ********* **** the ********* **-********-**/* **** *** ********** temperature ******** ** ****** ** ****. The ****** **** * *********** ************ algorithm ** ****** *** ******** **** temperature ** ***** **** *** ******** body ***********, ***** ** ****** ** products **** ******* ******* *************.
********* ********** **** *** ************ ********* “is **** *** *** ********* *********** screening ******* *******.” ********* **** **** issue **** ****’* ****** *********** ** their ****** ***** * -*.*°* ******:
***** *** ******** ** *** ********* camera ** ±*.*º*, ***** ** ****** of -*.*º* **** ****** *** *********** of *** ********** **********. ** *** not ******** **** *** **** ********** the ******, *** ** ******* **** correct *********** ***** **** ******** ** test ******* ****** ** *** ******* devices ********* ** **** *****.
****’* ****** *********** *** ***** ** instructions ***** ** ********* ** ****. Their ************ **** ** ****** *** reading ** *** ***** **** **°* when *** ****** ********* ******* *** accuracy ***** ********* * ***** **** at **°*. ** ***** ** *** study's *******, **** * -*.*°* ****** the ****** **** **°* **** *** black **** ** **°*. ********, ** fixed ****** ***** ***** ****** *** results ** *** *****. ** ***** merely ***** *** ********* ******’* *******, but *** ****** *** ********** *********** values ********** **** ****.
*************** **** ****. **** ****!
* *** ********* ** *** ********** from *** *********. ** **** **** of ** ****.
**** ******** "*************" ******* *** ********** were ******* ********* ** ***** *** products. **** **** ***** ******* ** the **** *** **** ********. ****'* very ******* **** ***** *** ** solid ********* ********* *** ****.
** *** *** **** **** *** simply * **** ** ******. ************* are ******** *** *** *** ** the **** ***** **********, *******, ***** venues *** ********* ** *** ***** are **** **** ******* **** **** will ** ******* ** **** * few *****.
**** **** ****** **** ** ******* for *** ******* ** *** ***** camera **** ****. **** **** ********* from *** *****. **** **** *** high **** ***** ***** ************ ******* themselves ** ************. **** **** ***** and ******* ** *********.
* ** **** ***** *** ***** to ** **** ** ********* (********* ones, ** **********). ** *** ***** to ****** ****...
** *** **** *** **** *** do *** **** ******? **** ******* to **** **** ***** *** ** opine ** ********* **** ****...
***, ***** **** **** *** ** getting ** *********. * **** ******* to *** **** ********** ******.
** *** ****, ** **** *** referenced ** *** **** ****** ** something **** (***** **** ******** **** and **** ********** **** *******)? *** how *** *** *** *** ******** from **-***, **** ***** ***** ******** with * ***** ** ********* ************?
** **** * ********* ** *** a ***** *********** *** ** ****** testing *** ********** ******* *******. **, this ** ********** ** *** ********* temperature.
*** ****** **** *** **** ** just ********. *****, ***** **** ** helping ****** **** *****, ****!
*********** ******* ** *** **** ******* about *** * ********* ******** ** stood ******* ** *** **** ** beat *** *********** ********* ***** ** was ******* * ****** *****:
** ** ****** **** ******* *** Pfizer ****** *****, * *** ******* a ****** *********** ** ********* **** ran *** **** ** ** ***** denied ******** ** *** *** *** my ***** ****. ** * *********, I **** **** ******** ******** *********** "remembers" ***** ** *** **** *** at ***** ******* *******. * ****** 100 ***** **** **** *** ******* building *** ****** **** *** ******* lot ** * ****** *** **** the ****** *******. ** "***********" *** 93F ***** ** ****** ** **** than *** **** ** *** ******* claiming "**** *********** ** ***." **** let ** ** *** *** *** test.
******** *** **** *********** ** *** best **** ** * ******'* *********** and ** *** ** *** ***** I *********! *** *****, ****** *** anyone *** ** **. *** *** need ** * ***** ****** ** one **** (**** * ****), ***** the **** ******* *** **** *** get **** **** ** ***** ** warmer (******* **** **** **). *** a **** **** ****** ***** **** the ****, **** ***** ** ***** 2-4 ******* ** *** **** *** then **** **** *** ** *** another **** ****** ~** ******* ** so *** *** ******** *** ** increase ** *** ******** **** *********** by ** ***** * ***** ** that ******** ** **** *********** (** a ** ****** ****, *** ****** see ** ***** ** ********). * have *** *** **** * ****** that ****** **** **** (****** *** Fever *******).
* ***'* **** ***** ********, *** while ******* ** *** *ã* ***** mall ****, * ******* ** ***** one **** ***** ********* **** ***** cameras *** ******** ******* ** *** high **°* (*******).
***** ******* ***** ****** *** ** bad **** *** ******** *********. **** should *** ** *********** ******** & the **** ******* *** ****** **** be ***** ***** ***** ****.
*** ****** ***** ****** ** ****** & *** ****** ********, ******* ** importing **** **** ******** *******
**'* **** ******* **** *** ******** upon ******** ** ******* ***** ** these ******* ** *** **** **** and ***** ************** **** ***** ***** a ***-*********** ******* **** *** ****** threshold, *********, *** *** ******* ** a ********* **** **** ** * FDA ********* ******.
***** **** **** ******** ** ******** liability *** ******* "*********" ** *** part ** *** *** **** ** fraught **** ********** ** **** ** the ************, ******, ********* *** *****.
*********: * *** ***** **** **** in *** ****** **** * ***** the *** ** *** ********** **** with ***. *'** **** ** *** hospital ** * ********** *** * months, **** ** ***, *****, ********** and * **** **** ** ******* bills.
*** ***** *******: *** *** *** prove *** *** ** **** ****?
Defendant: * *** ****** ** **** ** *** ******. * **** ***** ********** *** ****** *** *** **********. **** **** *** ***** *** *** ** *** **** ***** ** *** ******** *******. ****, ** *** ********* **** ***** * **** ***** **** ** *** ****** ** * ******** ** ** *********.
*** ***** *******: **** *** *********** (whoever *** **** ** *** ** the ***** ** *** ***********) ********* a ***** ********* ****** **** ******** must **** *******, ** **'* ********** that *** *** **** **** **** as *** ***** ********* ****** ****** would **** ****** **** ****** ** the ********.
*********: *** ****, *** ****** *** installed ** *** *** ******** ***/**/*** was ** ********* ********.
***** ****** ******* (***** ** ****) to ******* *** *** *********.
**** * *****! * **** **** those ** *** ******** ******* ******** *** **** **** *********
***** **** *********. *** ** **** company *** *** ** ******* *** intentional **********.
*** ** **** ******* *** *** be ******* *** *********** **********
**** ** ****, *** ******* ** these ******** ********* **** ****** **** they ***** ** ****** *** ********** if **** ********* ***** ******** (***** ******* ** "If *** *** *** ****** ** fever *******, *** *** *** ***** everything *** *** ** **** **** people **** ***** ** ***********.").
*** ****, *** ****** *** ********* is *** *** ******** ***/**/*** *** it ********* ********.
*** ***’* *** ***** **** ** prove **** *** * *****?
*** ***'* ********* **** ** **** a ******** *********** ** **** *****.
***** ******* ********** (** *** **** of *** *** ****) ** ******, the **** **** *** *** **** installed **** ****** **** *** ***** intent ** ****** *** ********** ******* such *************** ******* ********* ** ***** ************ passing ******* *** ******* ************ **** **** ** **** ***** free *********** ***** **** *** ***** previous ********** *******. (*.*. ** ******* beyond ***** *******).
*** **** **** **** *** ********** diagnosed (*** ************ **** * ******** COVID *********) * **** ***** ** lieu ** * ****~ ** **** or **** ***** ***** **** **** had ***** **** ***** ********* ****** and *** ** ****** ******* **** he *** **** *** *********.
* ********* *** ***** ********* ****** failed ** ****** (******* ** *********), which ** *** **** ***** *** their ********* ********* - ***** *********. Yes **** ***** **** ******* ** was ***** *********, *** *** *** messaging **** ** ******.
***** ** ** ***** ******** *** these ******* ** *** ********* *********** their **************, ****** *** ******* *********.
* ***** *** *********'* ******* ** a ********* ****** ** * **** trial ** * *****. ** *** roles **** **** *** *** * parties **** ** *** ****** *** the **********/********* *** *** ************, ************. Good ****!
***, *'* *** * ******, *** I **** ** ** ****** ******* if ** **** ******.
* ********* *** ***** ********* ****** failed ** ****** (******* ** *********), which ** *** **** ***** *** their ********* ********* - ***** *********.
**, *** **** * ***** *** are ****** **** **** ** ***** manufacturers **** ** *** **** *** approved ******* ** *** ****** **********, they ***** ***** ** ****** ** an ************ ******** **** ** ****** another ********?
***** ** ******** *** ******* ** have *** ***** ********* ** *** be ****** ** ** *****?
*'* *** *** **, *** * think *** ****** ** **** ******** lies ** ******* *** *** **** was ******* ** ******** **** **** temp ********* ** ******* ***** ******.
** *** ***** ** **** **** temp ********* ** **** ***** ** detect * ****** ** ***** ******* of ********* *** *****. ** **** if *** ** ********** ***** **** a **** ******, **** ****** ********* to *** **** ****, ****** ****. glasses *** ***** **** ****, **** a ****** *** ****** *** *****'* still * **** ****** **** ********* isn't ***** ** ***** ****. ******* that, *** *** **** ******** ***** not **** * **** ****** ******** to ******* ********* ******* ****.
*** **** *** **** ** ******* who ******** **** *** *** ********** in ***** ** ****** **********, **** wearing, **********, ***. *** ****'* *** temp *********. **** *** ***** ** the *** *** *** ** *** studies **** **** ***** ********** **, chances *** *** **** **** *** a ********* ******* ****.
***** ****, *** ******* *** ******** with *** *** ******** *** **** temp *********. **** *** **** *** of *** **** ********* *** **** go "** ***** ** ** ***** and ****** ** ************ ******** * temp ********* ********". * ***** *** it ***** * ******** ********* **** less ** * ***********.
**** ******** ** ********** ***** **** stand ** ** **** ********* *** the **** ********** ***** *** *** company ******** ************** **** ***** **** a ********** ****** ** ***** * negative ****** *** ****** ** *** follow *** **********.
*** ** *** ********* *'** **** looking ** **** **** ** ********* are ******* ** *** ** ** addition ** ***** ********* ******* **** questionnaires *** *** ***** ********* *** guidelines ** ** ****** **********, **** use ***. ** **** ****** **** to ** ** *** **** **** screening ****** **** ** * ************ measure *** **** **** ****** *** rely ** ** ** *** **** method ** **** ***** ********* ****.
*** *** * **** ****** ****** it, ********* *** ********** **** *** to * ***** ** ****. **** screening ******* ** * ****** *** more ** *, *** **** *** you ******* ** *** *** * proper ******** ** *** ** * and *** *** **** * ******** case ** ******* **** ****?
*** *** ***** *** ***** ** the ****, ******* ****** * ***** device *** *** ******:
******** ******* '*******' * ***** ******* after *** ******* - *** ********** Post
*************** **** ****.
*** ******* ** ********** ****** *** now ********* *** *****: "******** ******** *****-** ***** ********* ******* using ******** ************ ************ ********* **** readings ** ******** *****":
** *** **** ** *** **** of ***** ******* ** ** *** figure *** **** ****** ** ******* are ********?
****, ***, *********** ***** ****** ********* *** **+ Relabelers.
*** ** *** ******** **** *** face **** ********** ** **** ***** common ******** ** **** ***** ************** is ********* / ***** ****** **** / ***. *******, ** *** *********** with ******* ***********, **** **** ****** to ** ********* ** *********** *********.
*** ** *** ******** **** *** face **** ********** ** **** ***** common ******** ** **** ***** ************** is ********* / ***** ****** **** / ***.
* **** **** *** ****** ***** defense. *** ****** ***** ** * couple ** ******** *** * ******* helping ** **.
**** ****** *** **** ******* **** Hikvision's ******** ** *** *****.
**** ** * ********** ** * 5-month ******* *****, ** ******* ****, grew *** ** ** *********** ***-**** in-depth ****** ****** (****** ** *******) **** ******* ************** **** ******* misuses.
* ** **** ***** *** ***** to ** **** ** ********* (********* ones, ** **********). ** *** ***** to ****** **** ****** ** ***** take * *** ****, ** *** publication ** **** *** ***** ** due ** ****** **** *** ********** Post, *** ********** **** *** ***, etc.
****** ** *** **** - ** particular *****, *****, *****, **** *** spent ** **** **** ** *** paper - *** ** *** ** you *** **** ********* *** **** ethical *** ****** *** ** **** technology.